AnastoSEAL tackles gastrointestinal anastomotic leaks, affecting more than 1 in 10 patients among 14 million annual abdominal surgeries worldwide. Manifesting days post-surgery, these leaks cause delayed recoveries, soaring healthcare costs, and up to 33% mortality. Current solutions fail due to weak adhesion and lack of early detection. AnastoSEAL combines high-performance tissue adhesion with early leak detection using standard hospital imaging such as ultrasound and CT, replacing blind post-operative routine with confidence and clarity. Dr. Alexandre Anthis (CEO & founder) leads a team at Wyss Zurich combining product development experts with leading visceral surgeons. Addressing a $7B problem, AnastoSEAL aims to eliminate this deadly complication from care.